Form 4: Trevi Therapeutics Director Michael Heffernan Acquires 30,000 Stock Options

Director Michael Heffernan acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Summary

• On June 13, 2024, Michael Thomas Heffernan, a director of Trevi Therapeutics, Inc., acquired 30,000 nonstatutory stock options.
• The exercise price of these options is $2.77.
• The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative sentiment, but rather a standard corporate practice.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director could potentially increase shareholder confidence.

Key Dates